A Berwyn-based biopharmaceutical company is filing for a patent for its new drug candidate that could potentially treat neurodegenerative diseases. Annovis Bio filed for a patent for the “novel crystalline form” of buntanetap, writes John George for the Philadelphia Business Journal.  

This drug has a higher purity and longer half-life. Getting a 20-year patent would allow the company to continue developing drug therapies for neurological diseases, such as Parkinson’s and Alzheimer’s.  

Butantetap is supposed to improve the health of nerve cells, as well as decrease the levels of neurotoxic proteins. The phase 3 trial of the candidate will potentially be used as a treatment for early Parkinson’s disease.  

The study is expected to go until early 2024. The company went public at the beginning of 2020 raising $12 million in IPOs, it currently has five full-time employees.  

Read more about Annovis Bio in the Philadelphia Business Journal.  

More about Annovis Bio treatments.